Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levetiracetam for Hippocampal Hyperactivity in Individuals at Risk for Alzheimer's Disease
NCT07477431Phase 2Recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of levetiracetam in Alzheimer's disease (AD), sponsored by Sunnybrook Health Sciences Centre. Started Oct 2025; status: recruiting.
02
Drugs
levetiracetam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07477431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07477431.